TRAM
BMRN icon

Tuscan Ridge Asset Management’s BioMarin Pharmaceuticals BMRN Stock Holding History

Tuscan Ridge Asset Management’s Portfolio BMRN Stock Details BMRN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q1 		– Sell
-67,800
Closed -$5.77M – 593
2018
Q4 		$5.77M Buy
+67,800
New +$6.45M 0.57% 50

Other funds holding BMRN

Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
Sands Capital Management
Sands Capital Management Arlington, Virginia $25.5B AUM 26.46% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return
ClearBridge Investments
ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Tuscan Ridge Asset Management's BMRN Position: Q1 2019 in Review

Tuscan Ridge Asset Management sold out of BioMarin Pharmaceuticals (BMRN) in Q1 2019, closing a stake of 5,715 shares — an estimated $487K sold.

Tuscan Ridge Asset Management first reported a position in BMRN in Q4 2018 and held it in 1 quarter. The position peaked at $487K in Q4 2018. 486 funds tracked by Wall St. Rank hold BMRN as of Q1 2019.

  • Tuscan Ridge Asset Management reported no remaining BioMarin Pharmaceuticals position as of Q1 2019 after selling out during the quarter.
  • Tuscan Ridge Asset Management sold 5,715 BioMarin Pharmaceuticals shares in Q1 2019, an estimated $487K.
  • Tuscan Ridge Asset Management first reported a position in BioMarin Pharmaceuticals in Q4 2018 and held it in 1 quarter.
  • Tuscan Ridge Asset Management's BioMarin Pharmaceuticals position peaked at $487K in Q4 2018.
  • 486 funds tracked by Wall St. Rank held BioMarin Pharmaceuticals as of Q1 2019.

Based on Tuscan Ridge Asset Management's 13F filing for Q1 2019, filed 15 May 2019.